Milne Richard
Wellcome Genome Campus - Society and Ethics Research Group, Cambridge, UK.
Institute of Public Health, University of Cambridge, Cambridge, UK.
New Genet Soc. 2019 Jul 16;39(1):101-126. doi: 10.1080/14636778.2019.1637718. eCollection 2020.
In this paper I examine how the promissory value of genetics is constituted through processes of scale and scaling, focussing on the relationship between "rare" and "common" forms of disease. I highlight the bodies and spaces involved in the production of post-genomic knowledge and technologies of Alzheimer's disease and the development of new disease-modifying drugs. I focus on the example of the development of a monoclonal antibody therapy for Alzheimer's disease. I argue that the process of therapeutic innovation, from genetic studies and animal models to phase III clinical trials, reflects the persistent importance of a genetic imaginary and a mutually constitutive relationship between the rare and the common in in shaping visions of Alzheimer's disease medicine. Approaching this relationship as a question of scale, I suggest the importance of attending to how and where genomic knowledge is "scaled" or proves resistant to scaling.
在本文中，我探讨了遗传学的承诺价值是如何通过规模和规模化过程构建的，重点关注疾病“罕见”形式与“常见”形式之间的关系。我强调了参与阿尔茨海默病后基因组知识和技术生产以及新型疾病修饰药物开发的身体和空间。我聚焦于一种用于阿尔茨海默病的单克隆抗体疗法的开发实例。我认为，从基因研究、动物模型到III期临床试验的治疗创新过程，反映了基因想象的持续重要性以及罕见与常见在塑造阿尔茨海默病医学愿景方面的相互构成关系。将这种关系视为一个规模问题，我指出关注基因组知识如何以及在何处“规模化”或证明对规模化具有抗性的重要性。
